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Ravinder J. Singh
Mayo Clinic and Mayo Medical School, Rochester, Minnesota, USASponsored by ASMS, the 2007 Asilomar conference“Mass Spectrometry in Clinical Chemistry andMolecular Diagnostics” included 120 participants
from backgrounds as diverse as industry, instrumenta-
tion companies, hospitals, governmental laboratories,
reference laboratories, medical schools, and other aca-
demic institutions. The American Association for Clin-
ical Chemistry accredited this conference for ACCENT
continuing education credits.
Following opening comments by organizers Alan
Rockwood and Ravinder Singh, Jack Henion from Ad-
vion Biosciences presented “Can Mass Spectrometry
Add Value to Modern Clinical Chemistry?” which
overviewed the merits and issues pertaining to imple-
menting mass spectrometry (especially LC/MS) into
the modern clinical laboratory. Strengths and limita-
tions of mass spectrometry were described, emphasiz-
ing the value provided by LC/MS in clinical tests that
have historically employed immunoassay techniques.
Ambient ionization techniques, ion mobility, chip-
based nanospray, and others were also discussed.
Charles Cantor from SEQUENOM, Inc. and Boston
University School of Medicine then presented “SNP
Detection by Mass Spectrometry,” focusing on genetic
applications of mass spectrometry.
The session on Biomarker Applications and Genetic
Testing, chaired by Leigh Anderson, Plasma Proteome
Institute, led off with Anderson’s lecture, “Specific MS
Assays for Peptides and Proteins Using Selected Reac-
tion Monitoring and SISCAPA.” This described the
technique of “Standards and Capture by Anti-Peptide
Antibodies” (SISCAPA), essentially an immunoassay
with a mass spectrometer replacing the second (cap-
ture) antibody of a conventional immunoassay. Robert
Plumb from Imperial College, London, described “The
Application of High Resolution Liquid Chromatogra-
phy and High Resolution Exact Mass Spectrometry to
Investigate the Effects of Gut Microflora on Metabolism
and Toxicity.”
Andrew Hoofnagle from the Department of Labora-
tory Medicine, University of Washington, described in
“Clinical Tumor Marker Quantitation with LC/MS/
MS: Is There Hope?” thyroglobulin (an important tu-
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Immunoassays are unreliable in some patients due to
the presence of auto-antibodies that interfere with the
test. Hoofnagle’s approach solves the problems of en-
dogenous interfering antibodies (digest the sample into
peptides) and the lack of standardization between dif-
ferent commercial immunoassays (include an internal
standard peptide).
Christie Hunter from Applied Biosystems described
in “Peptide MRM-Based Assays in Plasma for Biomar-
ker Verification Studies,” the use of a triple quadrupole
linear ion trap mass spectrometer to create more than
1000 high quality, specific MRM transitions for multiple
peptides to many human plasma proteins. A non-
isobaric chemical labeling strategy was employed to
create global reference standards to enable quantitative
analysis. The session concluded with “Automated Nu-
cleic Acid Based Signature Sequence Analysis by
MALDI-TOF Mass Spectrometry—a Comparative Se-
quence Analysis Tool” by Christiane Honisch, Ph.D.,
SEQUENOM, Inc.
Russell Grant from Labcorp, Inc./Esoterix, chair of the
session “Instrumentation and Automation,” presented
“Application of Automation Tools in LC-MS/MS Assays
for Clinical Diagnostics.” He discussed a number of auto-
mation tools employed at LabCorp in development and
application of LC-MS/MS workflows, including smart
automation tools in optimization of method development.
The application of automation in the various components
of sample analysis were also discussed, including stag-
gered parallel multidimension LC systems. The goal of
automation in clinical testing was highlighted by compar-
ison to the existing autoanalyzer workflows utilized in
modern clinical diagnostics. Scott Kuzdzal from Perkin
Elmer, Life and Analytical Sciences, then presented
“Better Biomarkers by Bacon’s Bees.”
Donald H. Chace from Pediatrix Analytical chaired
the evening session “Metabolic Disorders” and pre-
sented “Beyond Newborn Screening: Clinical Mass
Spectrometry Application Expansion in the Next Ten
Years.” Newborn screening by mass spectrometry may
serve as a model for overall expansion of MS in the
clinical lab. The use of MS/MS in newborn screening
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1990s to several million specimens analyzed in year
2008. The success was based on several factors, one of
which is that tandem mass spectrometers have the
ability to measure complex profiles from a single small
sample.
Michael Morris, Clinical Operations Group, Waters
Corporation, presented “The Role of Time-of-Flight
Technology in Routine Clinical Applications.” Morris
reviewed clinical screening applications, including as-
pects of neonatal screening for inborn errors of metab-
olism. The criteria for identification of compounds by
mass spectrometry from a number of agencies (FDA,
EU, CAP, CLSI) were also reviewed, and ways of
meeting the criteria were discussed, including multiple
MRM transitions and exact mass measurement, and
theoretical versus experimental isotope ratio compari-
sons. The application of LC-TOF to the screening of a
panel of drugs implicated in drug-facilitated crime was
presented. The session concluded with “Tandem Mass
Spectrometry in Biochemical Genetics” by Dietrich Ma-
tern from Mayo Clinic College of Medicine.
Shalender Bhasin, Boston Medical Center, chaired
Sunday morning’s session “Quality, Clinical and Client
Perspectives, and Unmet Needs,” which highlighted
the challenges of making accurate sex steroid measure-
ments with the existing methodologies, and how mass
spectrometry can address current problems in patient
care. Also presented were perspectives on standardiza-
tion of test results and a summary of approaches for
rigorous method validation. William Rosner, St. Luke’s-
Roosevelt Hospital Center and College of Physicians
and Surgeons, Columbia University, presented “Assays
for Plasma Testosterone: What’s the Problem?” Maria
Ospina, Centers for Disease Control and Prevention
discussed “Harmonizing Testosterone Measurements—
CDC Perspective a.k.a. the CDC Sex Steroid Harmoni-
zation Project.” Steroid hormones measurements, espe-
cially of testosterone and estradiol, are increasingly
used in patient care at research. However, there are
problems with comparability and reliability of these
measurements. CDC’s steroid hormone standardization
project includes preanalytical, analytical, and postana-
lytical issues. Bhasin’s talk described “Population-
Based Reference Ranges for Sex Steroid Assays: The
Impact of Assay CV and Quality on Clinical Decision
Making.”
Russell Grant’s talk “Validation of Endogenous
Quantitative Assays with LC-MS/MS Technologies”
discussed a step-wise process flow to analytically vali-
date LC-MS/MS for utility in endogenous analyte mea-
surement in clinical diagnostics. The presentation high-
lighted experimental designs and failure analysis when
key components of assay validation were undertaken.
The talk also described streamlined workflows to estab-
lish assay stability.
The Sunday evening session, chaired by Pierre Chau-
rand, Vanderbilt University, covered Imaging and
Emerging Technologies. Gilbert S. Omenn, Universityof Michigan Medical School, described “Biomarker Dis-
covery from Tumor Tissues and Plasma” and demon-
strated the strategy of starting with evidence for tumori-
genic pathway mechanisms in the tumor and tracking the
corresponding protein biomarker candidates through
proximal biofluids to the plasma, using the Her2/neu
mouse model of human breast cancers and the androgen-
driven fusion gene TMPRSS2/ETS in human prostate
cancers. He also discussed the detection of autoantibod-
ies. This was followed by lecture by Dean Hafeman,
Protein Discovery Inc., “High Throughput Biomarker
Discovery and Small Molecule Quantification in Biolog-
ical Tissues using Parallel Electrochromatographic
Preparation.”
Pierre Chaurand in “Molecular Imaging of Tissue
Sections by MALDI Mass Spectrometry” described a
relatively new technology that can be used to locate
drugs, lipids, peptides, and proteins directly from the
surface of fresh frozen tissue sections. When analyzing
tissue sections for proteins, the profiles recovered typ-
ically contain about 500 distinct signals in the m/z range
up to 100,000. Thousands of proteomic profiles of
tissues sections can now be acquired from large sample
sets in very short periods of time.
The Monday morning session chaired by Steven
Soldin, Georgetown University, focused on Endocrine,
Drugs, and Toxicology. Soldin described “Tandem
Mass Spectrometry for Thyroid and Steroid Hormone
Replacement.” Following were Mary F. Lopez, Thermo
Fisher Scientific, “Targeted MS Quantitation of the
Anti-aging Hormone Klotho,” and Robert A. Middle-
berg, NMS Laboratories, “The Role of Mass Spectrom-
etry in TDM/Toxicology.”
In his talk “Toxic Trace Elements and the Role of
ICPMS,” Sum Chan, Quest Diagnostics, discussed
symptoms, and the physiological and molecular basis of
trace element toxicity, illustrating this with arsenic,
cadmium, lead, and mercury examples using induc-
tively coupled plasma-mass spectrometry (ICP-MS).
The principles and the variations of available hardware
such as nebulizers, RF generators, and collision/reaction
cells were given, as well as various strategies to deal with
interferences.
Steven Hofstadler, Ibis Biosciences, chaired the Mon-
day afternoon “Infectious Disease” session. In his talk
“High Throughput Analysis of Nucleic Acids for the
Identification and High Resolution Strain Typing of
Bacterial and Viral Pathogen,” Hofstadler described
using mass spectrometry, signal processing, and base
composition analysis of PCR amplification products to
identify microorganisms without the need for culture.
This is applicable to bacteria and viruses and has
recently been applied to mtDNA-associated mitochon-
drial diseases.
In his talk “Identification of Clinical Isolates of
Campylobacter (and Other Human Pathogens) by
MALDI-TOF-MS and Proteomics Identification of Their
Protein Biomarkers,” Clifton K. Fagerquist, Western Re-
gional Research Center, U.S. Department of Agriculture,
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of foodborne bacteria analyzed by MALDI-TOF-MS. Pro-
tein biomarkers (m.w. range 4–16 kDa) constitute a MS
profile or “fingerprint” allowing taxonomic classifica-
tion of an unknown isolate when compared with a
database MS spectra of known microbial isolates. Using
software tools, isolates were successfully “grouped”
and separated two distinct sub-species of Campylobacter
jejuni: C. j. jejuni and C. j. doylei. Finally, proteomics
techniques were used to detect amino acid substitutions
caused by mutations.
Randall W. Nelson, Intrinsic Bioprobes, Inc. and
Biodesign Institute at Arizona State University, pre-
sented the talk “The Use of Mass Spectrometric Immu-
noassay in the Study of Disease,” which described the
use of targeted mass spectrometric approaches to inves-
tigate microheterogeneity in human plasma proteins.
By understanding the breadth of protein diversity in the
“healthy” population, one can establish a baseline for
further investigations related to disease. Nelson also
discussed the potential of multiplexed mass spectro-
metric immunoassays to accurately detect and monitor
myocardial infarction and Type 2 diabetes.
Each of seventeen poster presenters gave five-minute
oral introductions to their posters:
1. Pavel Aronov, University of California, Davis.
Metabolic Profiling of Major Vitamin D Metabo-
lites Using Diels-Alder Derivatization and UltraPerformance Liquid Chromatography-Tandem
Mass Spectrometry.
2. David Johnson, Women’s and Children’s Hospital.
Chemical Derivative Design for High Sensitivity,
High Throughput MS/MS Clinical Assays.
3. Marta Kozak, Thermo Fisher Scientific. LC-MS/MS
Method for Quantitative Analysis of Tacrolimus,
Sirolimus, Everolimus, and Cyclosporin A in
Whole Blood Using TurboFlow Technology.
4. Mark Kushnir, ARUP Laboratories. High Sensitivity
Measurement of Estrogens in Serum by LC/MS/MS.
5. Stephanie Marin, ARUP Laboratories. Confirma-
tion of Benzodiazepines in Urine, Serum, Plasma,
and Meconium by LC/MS/MS.
6. Jim Settlage, Taylor Technology. Superiority of Gas
Chromatography/Tandem Mass Spectrometry As-
say (GC/MS/MS) for Estradiol for Monitoring of
Aromatase Inhibitor Therapy.
7. Robert White, Taylor Technology. Quantitation of
a Derivatized Synthetic Estrogen Extracted from
Rat Serum Using Gas Chromatography Electron
Capture Negative Ionization Tandem Mass Spec-
trometry (GC/ECNI/MS/MS).
8. Bingfang Yue. ARUP Laboratories. Direct Measure-
ment of Three Free Thyroid Hormones in Serum by
Equilibrium Dialysis (ED) and On-Line Solid Phase
Extraction (SPE) Liquid Chromatography/Tandem
Mass Spectrometry (LCMS/MS).
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filing Methods: LC-MS Versus Direct Infusion MS.
10. R. Brent Dixon, NC State University. Integrating
Voltage-Assisted Hydrodynamic Devices to Effi-
ciently Sample Biological Specimens.
11. Frank Kero, University of Florida. Development of
a Novel Screening Method for the Quality Assur-
ance of Exhaled Breath Condensates in the Clinical
Laboratory.
12. Hasmik Keshishnian, Broad Institute. Limits of
Quantitation for Low Abundance Proteins in
Plasma by Targeted MS.
13. Jihyeon Lim, Albert Einstein College of Medicine.
Global Proteomic Analysis Can Predict Clinical
Outcome and Disease Severity at Diagnosis in
Head and Neck Squamous Carcinoma.
14. Muhammad Najam-ul-Haq, University of Inns-
bruck. Diamond-Like Carbon (DLC) as LDI and
MALDI Target for Metabolomics, Peptidomics,
and Proteomics.
15. Elizabeth Pattison, ARUP Laboratories. LC/MS/MS
Analysis of Urine Cortisol and Cortisone by utilizing
high-Field Asymmetric waveform IonMobility Spec-
trometry (FAIMS).16. Drew Sauter, Nanoliter LLC. Nanoliter Sample
Handling: MALDI, Parallel LC/MALDI, Drug
Delivery, and Patient Sampling with Induction
Based Fluidics. Why the Nanoliter Regime Has
Merit.
17. Sergey Sikora, GenWay Biotech, Inc. Digging
Deeper into Proteome by IgY-Immunoaffinity
Fractionation.
David Herold, University of California, San Diego Med-
ical School and the Veterans Hospital, announced the
first annual “Mass Spectrometry Applications in the
Clinical Laboratory” conference, to be held November
1–5, 2008 at the Hilton, Mission Bay, San Diego, CA. It
will include a scientific program, posters, short courses,
exhibits, and industrial sponsored lunch presentations.
For additional information see http://www.msacl.org
or contact Dave at dherold@ucsd.edu or 858-552-8585
ext. 7758.
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